News

Molecular Partners Reports H1 2023 Corporate Highlights and Financials

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited...

read more

Kuros Biosciences Reports Results for First Half 2023

Schlieren (Zurich), Switzerland, August 9, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today reported a 148% growth in MagnetOs direct sales in the first six months of 2023. The enrollment of patients in the Phase II spine study for Fibrin-PTH was...

read more

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

Schlieren (Zurich), 20 July 2023 - LimmaTech Biologics AG (“LimmaTech Bio”), a clinicalstage biotech company developing vaccines for the prevention of life-threatening diseases, signed an in-license agreement with GlaxoSmithKline Biologicals SA (LSE/NYSE: GSK) enabling LimmaTech Bio to further develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis that GSK...

read more

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

Schlieren (Zurich), Switzerland, July 13, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the STRUCTURE trial, which is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in single-level transforaminal lumbar interbody fusion (TLIF) procedures in...

read more

Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its interim management statement for the quarter ending...

read more